ENDRA Life Sciences Files 8-K on Financials
Ticker: NDRA · Form: 8-K · Filed: Nov 15, 2024 · CIK: 1681682
| Field | Detail |
|---|---|
| Company | Endra Life Sciences INC. (NDRA) |
| Form Type | 8-K |
| Filed Date | Nov 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
TL;DR
ENDRA Life Sciences dropped an 8-K with financial updates. Check it out.
AI Summary
ENDRA Life Sciences Inc. filed an 8-K on November 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 3600 Green Court, Suite 350, Ann Arbor, MI 48105.
Why It Matters
This filing provides crucial updates on ENDRA Life Sciences' financial performance and operational status, which is important for investors and stakeholders to assess the company's health.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- ENDRA Life Sciences Inc. (company) — Registrant
- November 15, 2024 (date) — Date of Report
- 3600 Green Court, Suite 350, Ann Arbor, MI 48105 (location) — Principal executive offices
- Delaware (location) — State of incorporation
- 001-37969 (identifier) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on ENDRA Life Sciences Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on November 15, 2024.
Where are ENDRA Life Sciences Inc.'s principal executive offices located?
ENDRA Life Sciences Inc.'s principal executive offices are located at 3600 Green Court, Suite 350, Ann Arbor, MI 48105.
In which state was ENDRA Life Sciences Inc. incorporated?
ENDRA Life Sciences Inc. was incorporated in Delaware.
What is the Commission File Number for ENDRA Life Sciences Inc.?
The Commission File Number for ENDRA Life Sciences Inc. is 001-37969.
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-11-15 16:06:25
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share NDRA The Nasdaq Stock Mar
Filing Documents
- endra_8k.htm (8-K) — 24KB
- endra_ex991.htm (EX-99.1) — 120KB
- 0001654954-24-014547.txt ( ) — 275KB
- endra-20241115.xsd (EX-101.SCH) — 6KB
- endra-20241115_lab.xml (EX-101.LAB) — 14KB
- endra-20241115_cal.xml (EX-101.CAL) — 1KB
- endra-20241115_pre.xml (EX-101.PRE) — 9KB
- endra-20241115_def.xml (EX-101.DEF) — 2KB
- endra_8k_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On November 15, 2024, ENDRA Life Sciences Inc. issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated November 15, 2024, furnished herewith. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENDRA Life Sciences Inc. November 15, 2024 By: /s/ Richard Jacroux Name: Richard Jacroux Title: Chief Financial Officer 3